Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Issue published May 15, 2002 Previous issue | Next issue

  • Volume 109, Issue 10
Go to section:
  • In this issue
  • Perspectives
  • Commentaries
  • Research Articles
In this issue
In This Issue
John Ashkenas
John Ashkenas
Published May 15, 2002
Citation Information: J Clin Invest. 2002;109(10):1259-1259. https://doi.org/10.1172/JCI119950.
View: Text | PDF

In This Issue

  • Text
  • PDF
Abstract

Authors

John Ashkenas

×
Perspectives
Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways
Fabio Candotti, … , Roberta Visconti, John O’Shea
Fabio Candotti, … , Roberta Visconti, John O’Shea
Published May 15, 2002
Citation Information: J Clin Invest. 2002;109(10):1261-1269. https://doi.org/10.1172/JCI15769.
View: Text | PDF

Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways

  • Text
  • PDF
Abstract

Authors

Fabio Candotti, Luigi Notarangelo, Roberta Visconti, John O’Shea

×

IFNs and STATs in innate immunity to microorganisms
Thomas Decker, … , Mathias Müller, Pavel Kovarik
Thomas Decker, … , Mathias Müller, Pavel Kovarik
Published May 15, 2002
Citation Information: J Clin Invest. 2002;109(10):1271-1277. https://doi.org/10.1172/JCI15770.
View: Text | PDF

IFNs and STATs in innate immunity to microorganisms

  • Text
  • PDF
Abstract

Authors

Thomas Decker, Silvia Stockinger, Marina Karaghiosoff, Mathias Müller, Pavel Kovarik

×

JAK-STAT signaling in asthma
Alessandra B. Pernis, Paul B. Rothman
Alessandra B. Pernis, Paul B. Rothman
Published May 15, 2002
Citation Information: J Clin Invest. 2002;109(10):1279-1283. https://doi.org/10.1172/JCI15786.
View: Text | PDF

JAK-STAT signaling in asthma

  • Text
  • PDF
Abstract

Authors

Alessandra B. Pernis, Paul B. Rothman

×
Commentaries
Leptin: a novel therapeutic role in lipodystrophy
D.B. Savage, S. O’Rahilly
D.B. Savage, S. O’Rahilly
Published May 15, 2002
Citation Information: J Clin Invest. 2002;109(10):1285-1286. https://doi.org/10.1172/JCI15326.
View: Text | PDF

Leptin: a novel therapeutic role in lipodystrophy

  • Text
  • PDF
Abstract

Authors

D.B. Savage, S. O’Rahilly

×

Whence nitrotyrosine?
James K. Hurst
James K. Hurst
Published May 15, 2002
Citation Information: J Clin Invest. 2002;109(10):1287-1289. https://doi.org/10.1172/JCI15816.
View: Text | PDF

Whence nitrotyrosine?

  • Text
  • PDF
Abstract

Authors

James K. Hurst

×
Research Articles
Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells
Robert E. Schwartz, … , Wei-Shou Hu, Catherine M. Verfaillie
Robert E. Schwartz, … , Wei-Shou Hu, Catherine M. Verfaillie
Published May 15, 2002
Citation Information: J Clin Invest. 2002;109(10):1291-1302. https://doi.org/10.1172/JCI15182.
View: Text | PDF

Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells

  • Text
  • PDF
Abstract

We have derived from normal human, mouse, and rat postnatal bone marrow primitive, multipotent adult progenitor cells (MAPCs) that can differentiate into most mesodermal cells and neuroectodermal cells in vitro and into all embryonic lineages in vivo. Here, we show that MAPCs can also differentiate into hepatocyte-like cells in vitro. Human, mouse, and rat MAPCs, cultured on Matrigel with FGF-4 and HGF, differentiated into epithelioid cells that expressed hepatocyte nuclear factor-3β (HNF-3β), GATA4, cytokeratin 19 (CK19), transthyretin, and α-fetoprotein by day 7, and expressed CK18, HNF-4, and HNF-1α on days 14–28. Virtually all human, as well as a majority of rodent cells stained positive for albumin and CK18 on day 21; 5% (rodent) to 25% (human) cells were binucleated by day 21. These cells also acquired functional characteristics of hepatocytes: they secreted urea and albumin, had phenobarbital-inducible cytochrome p450, could take up LDL, and stored glycogen. MAPCs, which can be expanded in vitro and maintained in an undifferentiated state for more than 100 population doublings, can thus differentiate into cells with morphological, phenotypic, and functional characteristics of hepatocytes. MAPCs may therefore be an ideal cell for in vivo therapies for liver disorders or for use in bioartificial liver devices.

Authors

Robert E. Schwartz, Morayma Reyes, Lisa Koodie, Yuehua Jiang, Mark Blackstad, Troy Lund, Todd Lenvik, Sandra Johnson, Wei-Shou Hu, Catherine M. Verfaillie

×

Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins
Takafumi Yokota, … , Yuji Matsuzawa, Paul W. Kincade
Takafumi Yokota, … , Yuji Matsuzawa, Paul W. Kincade
Published May 15, 2002
Citation Information: J Clin Invest. 2002;109(10):1303-1310. https://doi.org/10.1172/JCI14506.
View: Text | PDF

Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins

  • Text
  • PDF
Abstract

Adiponectin, an adipocyte-derived hormone, was recently shown to have potential therapeutic applications in diabetes and obesity because of its influence on glucose and lipid metabolism. We found that brown fat in normal human bone marrow contains this protein and used marrow-derived preadipocyte lines and long-term cultures to explore potential roles in hematopoiesis. Recombinant adiponectin blocked fat cell formation in long-term bone marrow cultures and inhibited the differentiation of cloned stromal preadipocytes. Adiponectin also caused elevated expression of cyclooxygenase-2 (COX-2) by these stromal cells and induced release of prostaglandin E2 (PGE2). The COX-2 inhibitor Dup-697 prevented the inhibitory action of adiponectin on preadipocyte differentiation, suggesting involvement of stromal cell–derived prostanoids. Furthermore, adiponectin failed to block fat cell generation when bone marrow cells were derived from B6,129SPtgs2tm1Jed (COX-2+/–) mice. These observations show that preadipocytes represent direct targets for adiponectin action, establishing a paracrine negative feedback loop for fat regulation. They also link adiponectin to the COX-2–dependent PGs that are critical in this process.

Authors

Takafumi Yokota, C.S. Reddy Meka, Kay L. Medina, Hideya Igarashi, Phillip C. Comp, Masahiko Takahashi, Makoto Nishida, Kenji Oritani, Jun-ichiro Miyagawa, Tohru Funahashi, Yoshiaki Tomiyama, Yuji Matsuzawa, Paul W. Kincade

×

Myeloperoxidase produces nitrating oxidants in vivo
Joseph P. Gaut, … , Abderrazzaq Belaaouaj, Jay W. Heinecke
Joseph P. Gaut, … , Abderrazzaq Belaaouaj, Jay W. Heinecke
Published May 15, 2002
Citation Information: J Clin Invest. 2002;109(10):1311-1319. https://doi.org/10.1172/JCI15021.
View: Text | PDF

Myeloperoxidase produces nitrating oxidants in vivo

  • Text
  • PDF
Abstract

Despite intense interest in pathways that generate reactive nitrogen species, the physiologically relevant mechanisms for inflammatory tissue injury remain poorly understood. One possible mediator is myeloperoxidase, a major constituent of neutrophils, monocytes, and some populations of macrophages. The enzyme uses hydrogen peroxide and nitrite to generate 3-nitrotyrosine in vitro. To determine whether myeloperoxidase produces nitrating intermediates in vivo, we used isotope dilution gas chromatography/mass spectrometry to quantify 3-nitrotyrosine in two models of peritoneal inflammation: mice infected with Klebsiella pneumoniae and mice subjected to cecal ligation and puncture. Both models developed an intense neutrophil inflammatory response, and the inflammatory fluid contained markedly elevated levels of 3-chlorotyrosine, a marker of myeloperoxidase action. In striking contrast, 3-nitrotyrosine levels rose only in the mice infected with K. pneumoniae. Levels of total nitrite and nitrate were 20-fold higher in mice injected with K. pneumoniae than in mice subjected to cecal ligation and puncture. Levels of 3-nitrotyrosine failed to increase in mice infected with K. pneumoniae that lacked functional myeloperoxidase. Our observations provide strong evidence that myeloperoxidase generates reactive nitrogen species in vivo and that it operates in this fashion only when nitrite and nitrate become available.

Authors

Joseph P. Gaut, Jaeman Byun, Hung D. Tran, Wendy M. Lauber, James A. Carroll, Richard S. Hotchkiss, Abderrazzaq Belaaouaj, Jay W. Heinecke

×

Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes
Ripudaman S. Hundal, … , Steven E. Shoelson, Gerald I. Shulman
Ripudaman S. Hundal, … , Steven E. Shoelson, Gerald I. Shulman
Published May 15, 2002
Citation Information: J Clin Invest. 2002;109(10):1321-1326. https://doi.org/10.1172/JCI14955.
View: Text | PDF

Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes

  • Text
  • PDF
Abstract

Recent studies have implicated fatty acid-dependent activation of the serine kinase IKKβ, which plays a key role in tissue inflammation, in the pathogenesis of insulin resistance. High doses of salicylates have recently been shown to inhibit IKKβ activity and might therefore ameliorate insulin resistance and improve glucose tolerance in patients with type 2 diabetes. To test this hypothesis, we studied nine type 2 diabetic subjects before and after 2 weeks of treatment with aspirin (∼7 g/d). Subjects underwent mixed-meal tolerance tests and hyperinsulinemic-euglycemic clamps with [6,6-2H2]glucose to assess glucose turnover before and after treatment. High-dose aspirin treatment resulted in a ∼25% reduction in fasting plasma glucose, associated with a ∼15% reduction in total cholesterol and C-reactive protein, a ∼50% reduction in triglycerides, and a ∼30% reduction in insulin clearance, despite no change in body weight. During a mixed-meal tolerance test, the areas under the curve for plasma glucose and fatty acid levels decreased by ∼20% and ∼50%, respectively. Aspirin treatment also resulted in a ∼20% reduction in basal rates of hepatic glucose production and a ∼20% improvement in insulin-stimulated peripheral glucose uptake under matched plasma insulin concentrations during the clamp. In conclusion, these data support the hypothesis that IKKβ represents a new target for treating type 2 diabetes mellitus.

Authors

Ripudaman S. Hundal, Kitt F. Petersen, Adam B. Mayerson, Pritpal S. Randhawa, Silvio Inzucchi, Steven E. Shoelson, Gerald I. Shulman

×

Activation of the MEF2 transcription factor in skeletal muscles from myotonic mice
Hai Wu, Eric N. Olson
Hai Wu, Eric N. Olson
Published May 15, 2002
Citation Information: J Clin Invest. 2002;109(10):1327-1333. https://doi.org/10.1172/JCI15417.
View: Text | PDF

Activation of the MEF2 transcription factor in skeletal muscles from myotonic mice

  • Text
  • PDF
Abstract

Becker syndrome, a recessive nondystrophic myotonia caused by mutations in the chloride channel 1 gene (CLCN1), is characterized by delayed muscle relaxation after contraction. The ADR (arrested development of righting response) mouse is an animal model for Becker syndrome. Skeletal muscles from ADR myotonic animals show an increased number of oxidative fibers with a lack of glycolytic fibers as well as signs of muscle hypertrophy. Through breeding ADR myotonic mice with mice harboring a MEF2-dependent reporter gene, we found that the transcriptional activity of MEF2 was dramatically enhanced in myotonic muscles. Post-translational induction of MEF2 transcriptional activity correlated with the activation of p38 MAPK and did not affect MEF2 DNA-binding affinity. Expression of class II histone deacetylases (HDACs), which repress MEF2-dependent gene expression, was significantly reduced in skeletal muscles from myotonic mice. These findings suggest that the combined effects of class II HDAC deficiency and p38 MAPK activation lead to potent upregulation of MEF2 transcriptional activity, which contributes to the long-term changes in gene expression and fiber-type transformation observed in myotonic skeletal muscles. These findings provide new molecular targets for potential treatment of congenital myotonia.

Authors

Hai Wu, Eric N. Olson

×

Preterminal host dendritic cells in irradiated mice prime CD8+ T cell–mediated acute graft-versus-host disease
Yi Zhang, … , Adam J. Rivera, Stephen G. Emerson
Yi Zhang, … , Adam J. Rivera, Stephen G. Emerson
Published May 15, 2002
Citation Information: J Clin Invest. 2002;109(10):1335-1344. https://doi.org/10.1172/JCI14989.
View: Text | PDF

Preterminal host dendritic cells in irradiated mice prime CD8+ T cell–mediated acute graft-versus-host disease

  • Text
  • PDF
Abstract

To understand the relationship between host antigen-presenting cells (APCs) and donor T cells in initiating graft-versus-host disease (GVHD), we followed the fate of host dendritic cells (DCs) in irradiated C57BL/6 (B6) recipient mice and the interaction of these cells with minor histocompatibility antigen- (miHA-) mismatched CD8+ T cells from C3H.SW donors. Host CD11c+ DCs were rapidly activated and aggregated in the T cell areas of the spleen within 6 hours of lethal irradiation. By 5 days after irradiation, <1% of host DCs were detectable, but the activated donor CD8+ T cells had already undergone as many as seven divisions. Thus, proliferation of donor CD8+ T cells preceded the disappearance of host DCs. When C3H.SW donor CD8+ T cells were primed in vivo in irradiated B6 mice or ex vivo by host CD11c+ DCs for 24–36 hours, they were able to proliferate and differentiate into IFN-γ–producing cells in β2-microglobulin–deficient (β2m–/–) B6 recipients and to mediate acute GVHD in β2m–/– → B6 chimeric mice. These results indicate that, although host DCs disappear rapidly after allogeneic bone marrow transplantation, they prime donor T cells before their disappearance and play a critical role in triggering donor CD8+ T cell–mediated GVHD.

Authors

Yi Zhang, Jean-Pierre Louboutin, Jiang Zhu, Adam J. Rivera, Stephen G. Emerson

×

Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy
Kitt Falk Petersen, … , Phillip Gorden, Gerald I. Shulman
Kitt Falk Petersen, … , Phillip Gorden, Gerald I. Shulman
Published May 15, 2002
Citation Information: J Clin Invest. 2002;109(10):1345-1350. https://doi.org/10.1172/JCI15001.
View: Text | PDF

Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy

  • Text
  • PDF
Abstract

Lipodystrophy is a rare disorder that is characterized by selective loss of subcutaneous and visceral fat and is associated with hypertriglyceridemia, hepatomegaly, and disordered glucose metabolism. It has recently been shown that chronic leptin treatment ameliorates these abnormalities. Here we show that chronic leptin treatment improves insulin-stimulated hepatic and peripheral glucose metabolism in severely insulin-resistant lipodystrophic patients. This improvement in insulin action was associated with a marked reduction in hepatic and muscle triglyceride content. These data suggest that leptin may represent an important new therapy to reverse the severe hepatic and muscle insulin resistance and associated hepatic steatosis in patients with lipodystrophy.

Authors

Kitt Falk Petersen, Elif Arioglu Oral, Sylvie Dufour, Douglas Befroy, Charlotte Ariyan, Chunli Yu, Gary W. Cline, Alex M. DePaoli, Simeon I. Taylor, Phillip Gorden, Gerald I. Shulman

×

Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity
Volaluck Supajatura, … , Chisei Ra, Hideoki Ogawa
Volaluck Supajatura, … , Chisei Ra, Hideoki Ogawa
Published May 15, 2002
Citation Information: J Clin Invest. 2002;109(10):1351-1359. https://doi.org/10.1172/JCI14704.
View: Text | PDF

Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity

  • Text
  • PDF
Abstract

Toll-like receptor 2 (TLR2) and TLR4 play important roles in the early innate immune response to microbial challenge. To clarify the functional roles of TLRs 2 and 4 in mast cells, we examined bone marrow–derived mast cells (BMMCs) from TLR2 or TLR4 gene-targeted mice. Peptidoglycan (PGN) from Staphylococcus aureus stimulated mast cells in a TLR2-dependent manner to produce TNF-α, IL-4, IL-5, IL-6, and IL-13, but not IL-1β. In contrast, LPS from Escherichia coli stimulated mast cells in a TLR4-dependent manner to produce TNF-α, IL-1β, IL-6, and IL-13, but not IL-4 nor IL-5. Furthermore, TLR2- but not TLR4-dependent mast cell stimulation resulted in mast cell degranulation and Ca2+ mobilization. In a mast cell–dependent model of acute sepsis, TLR4 deficiency of BMMCs in mice resulted in significantly higher mortality because of defective neutrophil recruitment and production of proinflammatory cytokines in the peritoneal cavity. Intradermal injection of PGN led to increased vasodilatation and inflammation through TLR2-dependent activation of mast cells in the skin. Taken together, these results suggest that direct activation of mast cells via TLR2 or TLR4 by respective microligands contributes to innate and allergic immune responses.

Authors

Volaluck Supajatura, Hiroko Ushio, Atsuhito Nakao, Shizuo Akira, Ko Okumura, Chisei Ra, Hideoki Ogawa

×

Anabolic effects of a G protein–coupled receptor kinase inhibitor expressed in osteoblasts
Robert F. Spurney, … , Farshid Guilak, L. Darryl Quarles
Robert F. Spurney, … , Farshid Guilak, L. Darryl Quarles
Published May 15, 2002
Citation Information: J Clin Invest. 2002;109(10):1361-1371. https://doi.org/10.1172/JCI14663.
View: Text | PDF

Anabolic effects of a G protein–coupled receptor kinase inhibitor expressed in osteoblasts

  • Text
  • PDF
Abstract

G protein–coupled receptors (GPCRs) play a key role in regulating bone remodeling. Whether GPCRs exert anabolic or catabolic osseous effects may be determined by the rate of receptor desensitization in osteoblasts. Receptor desensitization is largely mediated by direct phosphorylation of GPCR proteins by a family of enzymes termed GPCR kinases (GRKs). We have selectively manipulated GRK activity in osteoblasts in vitro and in vivo by overexpressing a GRK inhibitor. We found that expression of a GRK inhibitor enhanced parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor-stimulated cAMP generation and inhibited agonist-induced phosphorylation of this receptor in cell culture systems, consistent with attenuation of receptor desensitization. To determine the effect of GRK inhibition on bone formation in vivo, we targeted the expression of a GRK inhibitor to mature osteoblasts using the mouse osteocalcin gene 2 (OG2) promoter. Transgenic mice demonstrated enhanced bone remodeling as well as enhanced urinary excretion of the osteoclastic activity marker dexoypyridinoline. Both osteoprotegrin and OPG ligand mRNA levels were altered in calvaria of transgenic mice in a pattern that would promote osteoclast activation. The predominant effect of the transgene, however, was anabolic, as evidenced by an increase in bone density and trabecular bone volume in the transgenic mice compared with nontransgenic littermate controls.

Authors

Robert F. Spurney, Patrick J. Flannery, Sanford C. Garner, Krairerk Athirakul, Shiguang Liu, Farshid Guilak, L. Darryl Quarles

×

Transcellular biosynthesis contributes to the production of leukotrienes during inflammatory responses in vivo
Jean-Etienne Fabre, … , Steven Offenbacher, Beverly H. Koller
Jean-Etienne Fabre, … , Steven Offenbacher, Beverly H. Koller
Published May 15, 2002
Citation Information: J Clin Invest. 2002;109(10):1373-1380. https://doi.org/10.1172/JCI14869.
View: Text | PDF

Transcellular biosynthesis contributes to the production of leukotrienes during inflammatory responses in vivo

  • Text
  • PDF
Abstract

Leukotrienes are lipid mediators that evoke primarily proinflammatory responses by activating receptors present on virtually all cells. The production of leukotrienes is tightly regulated, and expression of 5-lipoxygenase, the enzyme required for the first step in leukotriene synthesis, is generally restricted to leukocytes. Arachidonic acid released from the cell membrane of activated leukocytes is rapidly converted to LTA4 by 5-lipoxygenase. LTA4 is further metabolized to either LTC4 or LTB4 by the enzyme LTC4 synthase or LTA4 hydrolase, respectively. Unlike 5-lipoxygenase, these enzymes are expressed in most tissues. This observation previously has led to the suggestion that LTA4 produced by leukocytes may, in some cases, be delivered to other cell types before being converted into LTC4 or LTB4. While in vitro studies indicate that this process, termed transcellular biosynthesis, can lead to the production of leukotrienes, it has not been possible to determine the significance of this pathway in vivo. Using a series of bone marrow chimeras generated from 5-lipoxygenase– and LTA4 hydrolase–deficient mice, we show here that transcellular biosynthesis contributes to the production of leukotrienes in vivo and that leukotrienes produced by this pathway are sufficient to contribute significantly to the physiological changes that characterize an ongoing inflammatory response.

Authors

Jean-Etienne Fabre, Jennifer L. Goulet, Estelle Riche, MyTrang Nguyen, Kenneth Coggins, Steven Offenbacher, Beverly H. Koller

×

Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice
Tahar Hajri, … , Arend Bonen, Nada A. Abumrad
Tahar Hajri, … , Arend Bonen, Nada A. Abumrad
Published May 15, 2002
Citation Information: J Clin Invest. 2002;109(10):1381-1389. https://doi.org/10.1172/JCI14596.
View: Text | PDF

Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice

  • Text
  • PDF
Abstract

Deficiency of the membrane protein FAT/CD36 causes a marked defect in fatty acid uptake by various tissues and is genetically linked to insulin resistance in rats and humans. Here, we examined insulin responsiveness of CD36–/– mice. When fed a diet high in complex carbohydrates and low (5%) in fat, these animals cleared glucose faster than the wild-type. In vivo, uptake of 2-fluorodeoxyglucose by muscle was increased severalfold, and in vitro, insulin responsiveness of glycogenesis by the soleus was enhanced. Null mice had lower glycogen levels in muscle and liver, lower muscle triglyceride levels, and increased liver triglyceride content—all findings consistent with increased insulin-sensitivity. However, when the chow diet was switched to one high in fructose, CD36–/– mice but not wild-type mice developed marked glucose intolerance, hyperinsulinemia, and decreased muscle glucose uptake. High-fat diets impaired glucose tolerance equally in both groups, although CD36 deficiency helped moderate insulin-responsive muscle glucose oxidation. In conclusion, CD36 deficiency enhances insulin responsiveness on a high-starch, low-fat diet. It predisposes to insulin resistance induced by high fructose and partially protects from that induced by high-fat diets. In humans, CD36 deficiency may be an important factor in the metabolic adaptation to diet and in susceptibility to some forms of diet-induced pathology.

Authors

Tahar Hajri, Xiao Xia Han, Arend Bonen, Nada A. Abumrad

×
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts